Dopamine agonists alter neuroplasticity in LID

Home Forums Publications Dopamine agonists alter neuroplasticity in LID

Viewing 1 reply thread
  • Author
    • #2167

      Parkinson´s disease (PD) patients often receive combined pharmacotherapies where D2-class dopamine agonists are used as an adjunct to L-DOPA. We have now investigated the effects of this adjunct treatment at multiple levels and obtained some intriguing results…read the entire story in this paper:

      Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
      Espa E, Song L, Skovgård K, Fanni S, Cenci MA. Mov Disord. 2023 Jan 19. doi: 10.1002/mds.29301. Online ahead of print.
      PMID: 36656044

    • #2169

      Thank you for sharing this publication Angela!

Viewing 1 reply thread
  • You must be logged in to reply to this topic.